loading page

Molecular Imaging of Arterial and Venous Thrombosis
  • +1
  • Xiaowei Wang,
  • Melanie Ziegler,
  • James McFadyen,
  • Karlheinz Peter
Xiaowei Wang
Baker IDI Heart and Diabetes Institute
Author Profile
Melanie Ziegler
Baker Heart Research Institute - BHRI
Author Profile
James McFadyen
Baker Heart Research Institute - BHRI
Author Profile
Karlheinz Peter
Baker IDI Heart and Diabetes Institute
Author Profile

Abstract

Thrombosis contributes to one in four deaths worldwide and is the cause of a large proportion of mortality and morbidity. A reliable and rapid diagnosis of thrombosis will allow for immediate therapy, thereby providing significant benefits to patients. Molecular imaging is a fast-growing and captivating area of research, in both preclinical and clinical applications. Major advances have been achieved by improvements in three central areas of molecular imaging: 1) Better markers for diseases, with increased sensitivity and selectivity; 2) Optimised contrast agents with improved signal to noise ratio; 3) Progress in scanner technologies with higher sensitivity and resolution. Clinically available imaging modalities used for molecular imaging include, magnetic resonance imaging (MRI), X-ray computed tomography (CT), ultrasound, as well as nuclear imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT). In the preclinical imaging field, optical (fluorescence and bioluminescent) molecular imaging has provided new mechanistic insights in the pathology of thrombembolic diseases. Overall, the advances in molecular imaging, driven by the collaboration of various scientific disciplines, have substantially contributed to an improved understanding of thrombotic disease, and raises the exciting prospect of earlier diagnosis and individualised therapy for cardiovascular diseases. As such, these advances hold significant promise to be translated to clinical practice and ultimately to reduce mortality and morbidity in patients with thromboembolic diseases.

Peer review status:ACCEPTED

31 May 2020Submitted to British Journal of Pharmacology
03 Jun 2020Submission Checks Completed
03 Jun 2020Assigned to Editor
07 Jun 2020Reviewer(s) Assigned
17 Jun 2020Review(s) Completed, Editorial Evaluation Pending
25 Jun 2020Editorial Decision: Revise Minor
12 Aug 20201st Revision Received
18 Aug 2020Submission Checks Completed
18 Aug 2020Assigned to Editor
24 Aug 2020Reviewer(s) Assigned
05 Sep 2020Review(s) Completed, Editorial Evaluation Pending
23 Sep 2020Editorial Decision: Accept